Search Results - "Garcia Gil, Esther"

Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years by Korn, Stephanie, Bourdin, Arnaud, Chupp, Geoffrey, Cosio, Borja G., Arbetter, Doug, Shah, Mihir, Gil, Esther Garcia

“…Benralizumab is an IL-5Rα–directed monoclonal antibody indicated for patients with severe, uncontrolled eosinophilic asthma. To evaluate the long-term safety…”
Get full text

Baseline type 2 biomarker levels and response to tezepelumab in severe asthma by Corren, Jonathan, Pham, Tuyet‐Hang, Garcia Gil, Esther, Sałapa, Kinga, Ren, Pin, Parnes, Jane R., Colice, Gene, Griffiths, Janet M.

“…Background Tezepelumab is a human monoclonal antibody that blocks activity of thymic stromal lymphopoietin (TSLP). In the phase IIb PATHWAY study…”
Get full text

Asthma exacerbations are associated with a decline in lung function: a longitudinal population-based study by Soremekun, Seyi, Heaney, Liam G, Skinner, Derek, Bulathsinhala, Lakmini, Carter, Victoria, Chaudhry, Isha, Hosseini, Naeimeh, Eleangovan, Neva, Murray, Ruth, Tran, Trung N, Emmanuel, Benjamin, Garcia Gil, Esther, Menzies-Gow, Andrew, Peters, Matthew, Lugogo, Njira, Jones, Rupert, Price, David B

“…Progressive lung function (LF) decline in patients with asthma contributes to worse outcomes. Asthma exacerbations are thought to contribute to this decline;…”
Get more information

Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma by Kraft, Monica, Brusselle, Guy, FitzGerald, J Mark, Pavord, Ian D, Keith, Matthew, Fagerås, Malin, Garcia Gil, Esther, Hirsch, Ian, Goldman, Mitchell, Colice, Gene

“…Greater precision in asthma exacerbation risk prediction may improve outcomes. We sought to identify clinical characteristics and biomarkers associated with…”
Get full text

Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis by Canonica, Giorgio Walter, Harrison, Tim W., Chanez, Pascal, Menzella, Francesco, Louis, Renaud, Cosio, Borja G., Lugogo, Njira L., Mohan, Arjun, Burden, Annie, Garcia Gil, Esther

“…Background Clinically meaningful improvement in the Sino‐Nasal Outcome Test‐22 (SNOT‐22) was observed in patients with severe, eosinophilic asthma, and nasal…”
Get full text

Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT) by Bateman, Eric D, Chapman, Kenneth R, Singh, Dave, D'Urzo, Anthony D, Molins, Eduard, Leselbaum, Anne, Gil, Esther Garcia

“…The combination of aclidinium bromide, a long-acting anticholinergic, and formoterol fumarate, a long-acting beta2-agonist (400/12 μg twice daily) achieves…”
Get full text

Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study by JONES, Paul W, SINGH, Dave, BATEMAN, Eric D, AGUSTI, Alvar, LAMARCA, Rosa, DE MIQUEL, Gonzalo, SEGARRA, Rosa, CARACTA, Cynthia, GARCIA GIL, Esther

“…The efficacy and safety of two doses of aclidinium bromide were evaluated in patients with moderate to severe chronic obstructive pulmonary disease (COPD). In…”
Get full text

Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use by Jackson, David J., Burhan, Hassan, Menzies-Gow, Andrew, Pfeffer, Paul, Nanzer, Alexandra, Garcia Gil, Esther, Morris, Tamsin, Tran, Trung N., Hirsch, Ian, Dube, Sabada

“…Benralizumab is an IL-5 receptor alpha–directed cytolytic mAb that depletes eosinophils, reducing exacerbations and oral corticosteroid (OCS) use, and improves…”
Get full text

Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol by Singh, Dave, D'Urzo, Anthony D, Chuecos, Ferran, Muñoz, Anna, Garcia Gil, Esther

“…'Clinically important deterioration' (CID) is a composite endpoint measuring worsening of the key clinical features of chronic obstructive pulmonary disease…”
Get full text

Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers by Chapman, Kenneth R, Wise, Robert A, Scirica, Benjamin M, Bhatt, Deepak L, Daoud, Sami Z, Lythgoe, Dan, Gil, Esther Garcia

“…Beta-blocker therapies for cardiovascular comorbidities are often withheld in patients with chronic obstructive pulmonary disease (COPD) due to potential…”
Get full text

The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies by Jones, Paul W, Leidy, Nancy K, Hareendran, Asha, Lamarca, Rosa, Chuecos, Ferran, Garcia Gil, Esther

“…Reducing the severity of respiratory symptoms is a key goal in the treatment of chronic obstructive pulmonary disease (COPD). We evaluated the effect of…”
Get full text

Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study by Beier, Jutta, Kirsten, Anne-Marie, Mróz, Robert, Segarra, Rosa, Chuecos, Ferran, Caracta, Cynthia, Gil, Esther Garcia

“…This randomized, double-blind, Phase IIIb study evaluated the 24-hour bronchodilatory efficacy of aclidinium bromide versus placebo and tiotropium in patients…”
Get full text

The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic Dermatitis by Soung, Jennifer, Laquer, Vivian, Merola, Joseph F., Moore, Angela, Elmaraghy, Hany, Hu, Chaoran, Piruzeli, Maria Lucia Buziqui, Pierce, Evangeline, Garcia Gil, Esther, Jarell, Abel D.

“…Introduction Lebrikizumab, a high-affinity IgG4 monoclonal antibody that selectively inhibits interleukin-13 with high binding affinity and slow dissociation…”
Get full text

Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial by Menzies-Gow, Andrew, Corren, Jonathan, Bel, Elisabeth H., Maspero, Jorge, Heaney, Liam G., Gurnell, Mark, Wessman, Peter, Martin, Ubaldo J., Siddiqui, Shahid, Garcia Gil, Esther

“…Benralizumab is an interleukin-5 receptor α-directed cytolytic monoclonal antibody approved in several countries for the add-on maintenance treatment of…”
Get full text

ACCORD COPD II: A Randomized Clinical Trial to Evaluate the 12-Week Efficacy and Safety of Twice-Daily Aclidinium Bromide in Chronic Obstructive Pulmonary Disease Patients by Rennard, Stephen I., Scanlon, Paul D., Ferguson, Gary T., Rekeda, Ludmyla, Maurer, Brian T., Garcia Gil, Esther, Caracta, Cynthia F.

“…Background and Objectives Aclidinium bromide is a long-acting muscarinic antagonist approved for the long-term maintenance treatment of bronchospasm associated…”
Get full text

The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis by Miravitlles, Marc, Chapman, Kenneth R, Chuecos, Ferran, Ribera, Anna, Gil, Esther Garcia

“…Patients with chronic obstructive pulmonary disease (COPD) experience respiratory symptoms, which impair quality of life. This pooled analysis of two Phase III…”
Get full text

Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trial by Schmid, Karin, MD, Pascual, Silvia, MSc, Gil, Esther Garcia, MD, Ortiz, Stephan, RPh, PhD, Jansat, Josep M., PhD

“…Abstract Background: Aclidinium bromide is an inhaled, long-acting muscarinic antagonist currently in development for the treatment of chronic obstructive…”
Get full text

Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD by D’Urzo, Anthony, Singh, Dave, Garcia Gil, Esther

“…Bronchodilator therapy is the backbone of the management of chronic obstructive pulmonary disease. In some patients, inhaled corticosteroids can be prescribed…”
Get full text

Impact of patients' satisfaction with their inhalers on treatment compliance and health status in COPD by Chrystyn, Henry, Small, Mark, Milligan, Gary, Higgins, Victoria, Gil, Esther Garcia, Estruch, Jordi

“…Summary Objective To examine the relationships between inhaler satisfaction, treatment compliance and health status in patients with chronic obstructive…”
Get full text

Impact of season and geography on CompEx Asthma: a composite end-point for exacerbations by Jauhiainen, Alexandra, Scheepers, Lieke E J M, Fuhlbrigge, Anne L, Harrison, Tim, Zangrilli, James, Garcia Gil, Esther, Gustafson, Per, Fagerås, Malin, Da Silva, Carla A

“…CompEx Asthma, a novel composite end-point combining severe exacerbations (SevEx) with asthma-worsening events, was recently developed. Further…”
Get full text